

World Health Organization Approves SK bioscience as a Supplier of Novavax Nuvaxovid™ COVID-19 Vaccine

September 2, 2022

Novavax today announced that the World Health Organization (WHO) has approved a variation to allow SK bioscience to manufacture and supply the active substance in the Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine. This variation approval enables Novavax to manufacture product for countries who recognize WHO exceptional use license from two major vaccine suppliers – SK bioscience and the Serum Institute of India. This approval is the first Coalition for Epidemic Preparedness Innovations (CEPI)-funded network production for Novavax.

SK bioscience currently manufactures drug substance and drug product of Nuvaxovid for the South Korean market, drug substance for the [European Union](#), and now, drug substance for the WHO as well.

Trade Name in the U.S.

The trade name Nuvaxovid™ has not yet been approved by the U.S. Food and Drug Administration.